If you are searching for the Wegovy 7.2mg price UK, you are looking for the highest approved weekly dose of semaglutide for weight management in the UK. The MHRA authorised the 7.2mg dose in January 2026 for adults with obesity, and a single dose 7.2mg pen was approved in April 2026.
The 7.2mg dose is not a starting dose. It is an additional maintenance option for some adults with obesity who have already reached 2.4mg and have remained on that dose for at least 4 weeks. This guide explains what the 7.2mg dose is, how the dosing works, what affects the price, who may be eligible and how it compares with 2.4mg Wegovy and Mounjaro.
What Is Wegovy 7.2mg?
Wegovy 7.2mg contains semaglutide, the same active ingredient used in the lower Wegovy doses. It is manufactured by Novo Nordisk and is authorised in the UK for weight management in adults with obesity, alongside a reduced calorie diet and increased physical activity. The 7.2mg dose is not intended for people starting Wegovy for the first time.
For adults with obesity, the usual Wegovy treatment starts at 0.25mg once a week. The dose is then increased every 4 weeks until 2.4mg is reached. If needed, the dose can be increased to 7.2mg after a minimum of 4 weeks on 2.4mg, following an assessment by the prescriber.
When the 7.2mg dose was first authorised in January 2026, it was given as three 2.4mg injections on the same day. A single dose 7.2mg Wegovy pen was subsequently approved by the MHRA in April 2026. Therefore, the exact way you receive the 7.2mg dose depends on the pen supplied to you.
Wegovy is injected under the skin of the abdomen, thigh or upper arm. The injection site can be changed. If three 2.4mg injections are being used to provide the 7.2mg dose, the injections should be at least 5cm apart and a new needle should be used for each injection.
If you are switching from another weight management medicine such as Mounjaro (tirzepatide), do not try to match the doses yourself. The medicines use different active ingredients and dosing schedules. Your prescriber should decide which Wegovy dose is appropriate for you.
Wegovy works by mimicking a hormone called glucagon like peptide 1 (GLP 1). It acts on areas of the brain involved in appetite and also slows stomach emptying. This can help reduce food intake as part of a reduced calorie diet and increased physical activity.
Wegovy 7.2mg Price UK: Current Cost Breakdown
The price you pay for Wegovy can vary between pharmacies and online providers. The figures below show the pricing structure provided for this guide and should be treated as examples rather than a fixed UK wide price.
Dose Escalation Pricing Table
| Dose | Typical Price | Stage |
|---|---|---|
| 0.25mg | £79.99 | Starting dose (weeks 1–4) |
| 0.5mg | £94.99 | Escalation (weeks 5–8) |
| 1mg | £99.99 | Escalation (weeks 9–12) |
| 1.7mg | £139.99 | Escalation (weeks 13–16) |
| 2.4mg | £209.99 per month | Standard maintenance dose |
Based on these example prices, the first 16 weeks would total approximately £524.96 before the 2.4mg maintenance stage. The actual amount you pay can vary depending on the provider, consultation fees, delivery charges, promotions and whether you choose a multi month supply.
A three pen, 12 week maintenance bundle may be priced around £649.99, while a two pen, eight week bundle may be around £419.99. These are provider specific prices, not standard UK prices. Check the current price and the number of doses included before ordering.
The price of the 7.2mg dose can also depend on whether you receive the single dose 7.2mg pen or, where applicable, three 2.4mg doses. The single dose 7.2mg pen is now authorised in the UK, so older information saying that a standalone 7.2mg pen is not available is no longer current.
Prices can change, so confirm the current cost, consultation fees and delivery charges with your pharmacy before ordering.
Is Wegovy 7.2mg Right for You? Eligibility Explained
The 7.2mg dose has specific eligibility requirements. For weight management, it is authorised for adults with obesity, which means a BMI of 30kg/m² or higher. The MHRA specifically states that the 7.2mg dose does not apply to people with a BMI below 30kg/m² who are using Wegovy for weight management.
The standard Wegovy weight management indication has broader eligibility criteria at lower doses, including adults with overweight and a weight related health problem. However, this does not mean that everyone who qualifies for Wegovy at a lower dose will qualify for the 7.2mg dose.
If you are already using Wegovy 2.4mg, the 7.2mg dose may be considered after you have been on 2.4mg for at least 4 weeks if your prescriber considers an increase appropriate. It should not be treated as an automatic next step.
For NHS treatment, access is more restricted. NICE recommends semaglutide for certain adults with obesity through a specialist weight management service, alongside a reduced calorie diet and increased physical activity. The NICE criteria include a BMI of at least 35kg/m² with at least one weight related health condition, or a BMI of 30 to 34.9kg/m² with at least one weight related health condition and meeting the relevant criteria for referral to a specialist weight management service.
Private prescribing and NHS prescribing follow different assessment and access arrangements. A private prescription does not automatically mean you meet the criteria for NHS treatment.
You May Be Suitable If:
- You are an adult with a BMI of 30kg/m² or above and are being assessed for Wegovy weight management
- You have already reached the 2.4mg Wegovy dose and have been taking it for at least 4 weeks, if your prescriber considers an increase appropriate
- You are able to follow the diet and physical activity advice that forms part of your weight management plan
- Your prescriber has reviewed your medical history and considers the 7.2mg dose appropriate for you
Speak to a Prescriber First If You Are:
- Pregnant, planning a pregnancy or breastfeeding
- Living with a personal or family history of certain thyroid cancers
- Managing a pancreatic or digestive condition
- Under the age of 18
This is general information only. Your prescriber will assess your individual circumstances and decide whether Wegovy and the prescribed dose are suitable for you.
How Wegovy Works
Semaglutide belongs to a group of medicines called GLP 1 receptor agonists. It acts on parts of the brain involved in appetite and can help reduce hunger and increase feelings of fullness. It also slows stomach emptying.
Wegovy is used alongside a reduced calorie diet and increased physical activity. It is not intended to replace healthy eating or physical activity as part of a weight management plan.
Clinical Evidence Behind Wegovy and the 7.2mg Dose
Wegovy 2.4mg has been studied extensively in the STEP clinical trial programme. In STEP 1, adults receiving semaglutide 2.4mg alongside lifestyle changes had an average weight loss of about 15% after 68 weeks, compared with about 2.4% with placebo. These are average results from a clinical trial and do not predict how much weight an individual person will lose.
The STEP 1 extension also showed that participants regained a significant amount of weight after stopping semaglutide treatment. This is one reason weight management treatment may need to be considered as part of longer term care rather than as a short course.
The higher 7.2mg dose was studied in the STEP UP trial, a Phase 3b study involving adults with obesity. Participants received 7.2mg, 2.4mg or placebo alongside lifestyle intervention for 72 weeks. The study found greater average weight loss with 7.2mg than with 2.4mg.
The trial reported average weight loss of about 20.7% with 7.2mg and about 17.5% with 2.4mg at 72 weeks. These figures describe the study groups and should not be treated as a promise of the result an individual will achieve. The higher dose may also cause gastrointestinal side effects, so your prescriber should consider tolerability when deciding whether an increase is appropriate.
Wegovy 7.2mg vs 2.4mg vs Mounjaro: How Do They Compare?
| Treatment | Typical Average Weight Loss | Dosing | UK Status |
|---|---|---|---|
| Wegovy 2.4mg | ~15% (STEP 1, 68 weeks) | Once weekly, self injected | Available privately and through NHS services subject to eligibility |
| Wegovy 7.2mg | ~20.7% (STEP UP, 72 weeks) | Once weekly; single 7.2mg pen or three 2.4mg injections where applicable | Licensed for weight management in adults with obesity |
| Mounjaro (tirzepatide) | Higher average weight loss has been reported at higher doses in clinical studies | Once weekly, self injected | Available privately and through NHS pathways subject to eligibility |
These figures come from different studies and should not be used as a direct prediction of how one medicine will perform compared with another for an individual person.
If tirzepatide is of interest as an alternative or next step, our Mounjaro injection for weight loss page sets out current strengths, pricing and how Mounjaro differs from Wegovy in terms of its active ingredient and dosing. There is no medicine that is automatically "better" for everyone. The right option depends on your clinical circumstances, tolerability, treatment goals and your prescriber's assessment.
Buying Guide: What Affects the Price You See Online
Not all advertised Wegovy prices are directly comparable. Looking at what is included in the price can help you understand the actual cost of treatment.
Single Pens vs Bundles
A Wegovy pen can contain multiple weekly doses depending on the pen presentation. The newer 7.2mg pen is a single dose pen, while FlexTouch pens for the lower doses contain four weekly doses. Always check the specific pen supplied, the number of doses included and the price before ordering.
Multi pen bundles can make reordering less frequent, but they are not automatically cheaper. Check the cost per dose and any additional fees before deciding.
What's Included in the Advertised Price
Check whether the advertised price includes the clinical assessment, prescriber review, medicine and delivery. Also check whether there are additional charges for delivery, follow up or other services.
Hidden Fees to Watch For
Look carefully at subscription prices, introductory offers and automatic renewals. A lower first order price may not be the same as the provider's standard ongoing price.
Before ordering, check the full amount you will pay and whether the price changes after the first order.
Why Prices Vary Between Providers
Prices can differ between providers for several reasons, including the pharmacy's pricing, clinical support, delivery arrangements and other service costs. If you are ordering prescription only medicine online, check that the pharmacy is registered with the General Pharmaceutical Council (GPhC).
How to Order: The Assessment and Delivery Process
Getting started usually involves a clinical assessment covering your medical history, current medicines and weight management needs. A prescriber then decides whether Wegovy is appropriate and which dose is suitable.
If treatment is prescribed, the medicine should be supplied by a legitimate pharmacy. Delivery arrangements vary between providers, so check how your medicine will be packaged and transported.
Wegovy is temperature sensitive and must be stored according to the instructions for the specific pen. The product information supports controlled shipment at temperatures below 30°C for up to 48 hours.
Storage and Practical Considerations
Storage instructions depend on which Wegovy pen you receive.
Before first use, Wegovy should generally be stored in a refrigerator between 2°C and 8°C and should not be frozen.
For the 7.2mg single dose pen, the product information states that it can be stored unrefrigerated for up to 28 days at a temperature not above 30°C. It should be discarded if it has been out of the refrigerator for more than 28 days.
The lower dose FlexTouch pens have different in use storage instructions. They can be kept for up to 6 weeks below 30°C or in a refrigerator after first use.
Always check the patient information leaflet supplied with your specific pen rather than applying the storage rules for one Wegovy presentation to another.
Frequently Overlooked Considerations Before You Start
- Dose escalation should follow your prescriber's instructions. The standard schedule increases the dose every 4 weeks, and the 7.2mg dose should only be considered after at least 4 weeks on 2.4mg.
- If you develop significant gastrointestinal symptoms, your prescriber may decide to delay the next dose increase or return you to the previous dose until your symptoms improve.
- Results vary between individuals, and average clinical trial results are not a guarantee of personal weight loss.
- Weight management medicines are intended to be used alongside lifestyle changes rather than as a replacement for them.
- If your weight management needs or health circumstances change, speak to your prescriber about whether your current treatment remains appropriate.
- You can also explore our Weight Loss Hub to learn more about weight management options available in the UK.
UK Obesity Context: Why This Matters
Obesity remains a significant health issue in England. According to the Health Survey for England 2024, 30% of adults were living with obesity and 66% were overweight or living with obesity overall.
This helps explain the growing focus on weight management services and medicines such as semaglutide. However, access to these medicines depends on the treatment indication, eligibility criteria and whether treatment is being provided privately or through the NHS.
For NHS prescribing, NICE recommends semaglutide within specialist weight management services for eligible adults and alongside a reduced calorie diet and increased physical activity.
Medical Disclaimer
This article is provided for general informational purposes only and does not constitute medical advice. Wegovy (semaglutide), including the 7.2mg dose, is a prescription only medicine and should only be used under the supervision of an appropriately qualified UK prescriber following an individual clinical assessment.
Prices mentioned in this guide can vary between pharmacies, treatment plans and promotions, and may change over time. Always check the current price and what is included in your treatment package before ordering from a GPhC registered pharmacy.
Results can vary from person to person. Average results reported in clinical trials do not guarantee the same outcome for an individual. This content does not replace advice from your GP, prescriber or pharmacist and should not be used to self diagnose or self treat a condition.
If you experience side effects, have concerns about your treatment, or are unsure about your dose, speak to your prescriber or pharmacist for advice. If you develop severe or urgent symptoms, seek appropriate medical help.
